[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lb Pharmaceuticals Inc (LBRX)

Lb Pharmaceuticals Inc (LBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 912,184
  • Shares Outstanding, K 28,676
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,210 K
  • EBIT $ -21 M
  • EBITDA $ -30 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.78
  • Number of Estimates 4
  • High Estimate $-0.62
  • Low Estimate $-1.10
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.51 +36.89%
on 03/31/26
33.47 -7.93%
on 04/27/26
+6.98 (+29.26%)
since 03/27/26
3-Month
20.46 +50.61%
on 01/30/26
33.47 -7.93%
on 04/27/26
+9.58 (+45.08%)
since 01/28/26

Most Recent Stories

More News
LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia

Pivotal Phase 3 NOVA-2 trial in schizophrenia ongoing, topline data expected in 2H 2027 LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NEW YORK, April 22,...

LBRX : 31.20 (-1.93%)
LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference

NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for...

LBRX : 31.20 (-1.93%)
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)

NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for...

LBRX : 31.20 (-1.93%)
LB Pharmaceuticals Inc.: Q4 Earnings Snapshot

LB Pharmaceuticals Inc.: Q4 Earnings Snapshot

LBRX : 31.20 (-1.93%)
LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Reported positive results from potentially registrational Phase 2 trial of LB-102 in schizophrenia Advanced LB-102 into late-stage development in multiple indications with initiation of a pivotal...

LBRX : 31.20 (-1.93%)
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia

LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to evaluate change in PANSS total score...

LBRX : 31.20 (-1.93%)
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors

NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for...

LBRX : 31.20 (-1.93%)
LB Pharmaceuticals to Participate in Upcoming March Investor Events

NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for...

LBRX : 31.20 (-1.93%)
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Dr. Minako Pazdera, the new General...

LBRX : 31.20 (-1.93%)
LB Pharmaceuticals Announces $100.0 Million Private Placement

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for...

LBRX : 31.20 (-1.93%)

Business Summary

LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression and other neuropsychiatric diseases. LB Pharmaceuticals is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 36.00
2nd Resistance Point 34.74
1st Resistance Point 33.27
Last Price 31.20
1st Support Level 30.54
2nd Support Level 29.28
3rd Support Level 27.81

See More

52-Week High 33.47
Last Price 31.20
Fibonacci 61.8% 25.79
Fibonacci 50% 23.42
Fibonacci 38.2% 21.04
52-Week Low 13.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.